1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2025

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | December 13, 2024 at 13:00:00 EET

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2025

BBS-Bioactive Bone Substitutes Plc (“BBS”) will publish its financial reports for 2025 as follows:

ReportDate
Financial statements release for 2024February 21, 2025
Annual report 2024Week commencing on March 17, 2025
Half-year report January – June, 2025August 29, 2025

BBS-Bioactive Bone Substitutes Plc observes a silent period before publishing financial reports. The silent period preceding the publication of the financial statement release is four weeks.

The Annual General Meeting of BBS-Bioactive Bone Substitutes Plc is scheduled to be held on Tuesday, April 29, 2025. The Board of Directors will convene the Annual General Meeting separately later.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2025

Datum 2024-12-13, kl 12:00
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2025